| Rosanne H Sandsbury, RN, NHCM | |
|
145 Sunset Drive, Belmont, NH 03220 | |
| (603) 556-7449 | |
| (603) 556-7449 |
| Full Name | Rosanne H Sandsbury |
|---|---|
| Gender | Female |
| Speciality | Midwife |
| Location | 145 Sunset Drive, Belmont, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033268297 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 05052208-21 (New Hampshire) | Secondary |
| 176B00000X | Midwife | 1023 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rosanne H Sandsbury, RN, NHCM 145 Sunset Drive, Belmont, NH 03220 Ph: (603) 556-7449 | Rosanne H Sandsbury, RN, NHCM 145 Sunset Drive, Belmont, NH 03220 Ph: (603) 556-7449 |
News Archive
Conservatives are accusing Democrats of politicizing Kennedy's death to pass health care legislation, Politico reports: "So his allies on the left have made no secret of their hopes that his legacy will serve to bolster the uncertain health reform plan, with Sen. Robert Byrd (D-W.Va.) even suggesting the bill be named for Kennedy.
The Danone Institute has provided a fellowship for basic research to Ana Antsn Solanas, a research assistant in the Dietetics and Diet Therapy Unit of the University of Navarra. With the help of this fellowship, the researcher will collaborate in a program for defining individualized treatments for each type of obesity.
The Bournemouth University-based Inforce Foundation has successfully completed one of the world's most unique training programmes which featured the construction and excavation of the world's first 'mock' mass grave.
This week's issue of the Lancet "has an HIV theme ahead of the International AIDS Society meeting in Washington, D.C., ... on July 22-27," a Lancet editorial states, noting, "The issue of antiretrovirals for prevention, specifically pre-exposure prophylaxis, is presently under intense debate."
Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.
› Verified 9 days ago